Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1285150 | 0.85 | PDE2A (0.42) | PDE2AHPGDPPARGCCR1 | |
| SCHEMBL1643774 | 0.83 | TP53 (0.55) | PDE2ATP53 | |
| SCHEMBL1644966 | 0.81 | KMT2A (0.51) | TP53PPARG | |
| SCHEMBL1644476 | 0.81 | HPGD (0.52) | HPGDTP53PPARG | |
| SCHEMBL1644493 | 0.80 | ALOX5 (0.57) | PDE2ATP53 | |
| SCHEMBL1643824 | 0.77 | ACACB (0.47) | HPGDTP53 | |
| SCHEMBL1644482 | 0.77 | ACACB (0.47) | HPGDTP53 | |
| SCHEMBL1643038 | 0.76 | ACACB (0.46) | HPGDTP53 | |
| SCHEMBL1645101 | 0.75 | ALDH1A1 (0.51) | HPGDTP53 | |
| SCHEMBL29342721 | 0.74 | PDE2A (0.50) | PDE2APPARGCCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | PDE2A 1116/4885HPGD 510/4885TP53 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.